
VICENTE DAMIÁN
ESCUDERO VILAPLANA
Profesor asociado
Publications (93) VICENTE DAMIÁN ESCUDERO VILAPLANA publications
2025
-
Empowerment among breast cancer survivors using an online peer support community
Supportive Care in Cancer, Vol. 33, Núm. 1
2024
-
Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors
European Journal of Hospital Pharmacy, Vol. 31, Núm. 5, pp. 409-415
-
Perceived quality of life by patients with immune-mediated inflammatory diseases treated with biological therapies. SACVINFA study
Farmacia Hospitalaria, Vol. 48, Núm. 6, pp. 265-271
-
Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient
Journal of Oncology Pharmacy Practice, Vol. 30, Núm. 7, pp. 1268-1273
-
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD)
Orphanet Journal of Rare Diseases, Vol. 19, Núm. 1
-
Validation of a Questionnaire to Assess the Usability of and User Experience with Mobile Health Applications
Healthcare (Switzerland), Vol. 12, Núm. 23
-
[Translated article] Development and consensus of a dashboard model to evaluate research activity in Spanish Hospital Pharmacy Services
Farmacia Hospitalaria, Vol. 48, pp. TS28-TS34
2023
-
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882
-
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
Journal of medical economics, Vol. 26, Núm. 1, pp. 445-453
-
Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain
BMC Pulmonary Medicine, Vol. 23, Núm. 1
-
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy
Frontiers in Oncology, Vol. 13
-
Possible heart failure caused by osimertinib in a lung cancer patient
Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 4, pp. 1015-1020
2022
-
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application
Frontiers in Oncology, Vol. 12
-
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital
Frontiers in Public Health, Vol. 10
-
Análisis coste-utilidad de venetoclax en combinación con obinutuzumab como tratamiento de primera línea de la leucemia linfocítica crónica en España
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 3, pp. 121-132
-
Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer
Frontiers in Oncology, Vol. 12
-
Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare
Frontiers in Immunology, Vol. 13
-
Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study
Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 12, pp. 2020-2029
-
Implantación de una metodología para evaluar patient‑reported outcomes en pacientes con cáncer de pulmón: Protocolo del estudio PeOpLe (Patient‑reported Outcomes in Lung cancer )
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 265-269
-
Implementation and evaluation of a home pharmaceutical care model through Telepharmacy
Farmacia Hospitalaria, Vol. 46, pp. 36-46